ДЕФИЦИТ АЛЬФА-1 - АНТИТРИПСИНА И ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ
Introduction. Alpha-1-antitrypsin deficiency (AATD) is a genetic disorder that manifests as pulmonary emphysema, liver cirrhosis and, rarely, as the skin disease panniculitis, and is characterized by low serum levels of AAT, the main protease inhibitor (PI) in human serum. The prevalence in Western Europe and in the USA is estimated at approximately 1 in 2,500 and 1 : 5,000 newborns, and is highly dependent on the Scandinavian descent within the population.
Chronic obstructive pulmonary disease (COPD) is one of the most essential causes of morbidity and mortality. In 2008, COPD was the fourth leading cause of death in the world, but the number of patients is still increasing and the World Health Organization (WHO) predicts that COPD will get the third most common cause of mortality in 2030.
The Aim. To acquaint the students and specialists of practical healthcare with a genetic disease, deficiency of alpha-1-antitrypsin
Меthods. The study of publications on this subject included in the evidentiary basis the Cochrane Library EMBASE and MEDLINE, databases during the last 30 years.
Results. The most common deficiency alleles in North Europe are PI Z and PI S, and the majority of individuals with severe AATD are PI type ZZ. Type ZZ and SZ AATD are risk factors for the development of respiratory symptoms (dyspnoea, coughing), early onset emphysema, and airflow obstruction early in adult life. Environmental factors such as cigarette smoking, and dust exposure are additional risk factors and have been associated to an accelerated progression of this condition. AATD is caused by mutations in the SERPINA 1 gene encoding AAT, and is inherited as an autosomal recessive trait. The diagnosis can be established by detection of low serum levels of AAT and isoelectric focusing, PCR. For treatment of lung disease, intravenous alpha-1-antitrypsin augmentation therapy, annual flu vaccination and a pneumococcal vaccine every 5 years are recommended. Relief of breathlessness may be obtained with long-acting bronchodilators and inhaled corticosteroids. The end-stage lung disease can be treated by organ transplantation.
Conclusions. Preventive measures, such as smoking cessation, avoiding contact with pollutants, vaccine prevention of infections are measures that reduce the rate of progression of the disease. It is advisable to pre-clinical diagnostic of alpha1-antitrypsin deficiency that could determine the choice of occupation, place of residence, the lifestyle of an individual.
Ardak N. Zhumagaliyeva, http://orcid.org/0000-0002-4928-1339
Semey State Medical University, Semey, Kazakhstan,
A PhD student on the specialty “Medicine”
1. AADRSG; Survival and FEV1 decline in individuals with severe deficiency of alpha-1 antitrypsin (Alpha-1 Antitrypsin Deficiency Registry Study Group). Am J Respir Crit Care Med. 1998, 158, pp.49–59.
2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis. 1986,136, pp.225–244.
3. [ATSERS] American Thoracic Society, European Respiratory Society: American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003, 168, pp.818-900.
4. Bao J. J., Sifers R. N. et al. Molecular evolution of serpins: homologous structure of the human α1-antichymotrypsin and 1-antitrypsin genes. Biochemistry. 1987, 26, pp. 7755–9.
5. Barker A. F., D’Silva R. G., Buist A. S. Lung function and alpha 1-AT deficiency. In: Crystal RG, ed. Alpha 1-antitrypsin deficiency: biology, pathogenesis, clinical manifestations, therapy. New York: Marcel Dekker, 1996, pp.245–57.
6. Barnes P. J. Chronic obstructive pulmonary disease. // N. engl. J.Med.2000, 343, pp.269-280
7. Barnett V. T., Sekosan M., Khurshid A. Wegener's granulomatosis and alpha1-antitrypsin-deficiency emphysema: proteinase-related diseases. Chest. 1999, 116, pp. 253–255.
8. Bascom R. Differential susceptibility to tobacco smoke: possible mechanism. Pharmacogenetics. 1991, 1, pp. 102-6.
9. Beckman L., Sikstrom C., Mikelsaar A., Krumina A., Kucinskas V., Beckman G. Alpha 1 - antitrypsin (PI) alleles as markers of Westeuropean influence in the Baltic Sea region. Hum Hered. 1999, 49(1), pp. 52-5.
10. Brantly M., Nukiwa T., Crystal R. G. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988, 84,pp.13–31
11. Brantly M. L., Paul L. D., Miller B. H., Falk R. T., Wu M. Clinical features and history of the destructive lung disease associated with alpha1 antitrypsin deficiency of adults with pulmonary symptoms. AmRevRespirDis. 1988 b,138, pp. 327-36.
12. Brantly M. L., Wittes J. T., Vogelmeier C. F., Hubbard R. C., Fells G. A., and Crystal R. G. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest. 1991, 100(3), pp. 703-8.
13. Campbell E. J. Alpha 1 - antitrypsin deficiency: incidence and detection program. Respir Med. 2000, 94, pp. 18–21.
14. Carrell R. W., Lomas D. A. Alpha1-antitrypsin deficiency – a model for conformational diseases. N Engl J Med. 2002, 346, pp. 45-53.
15. Carroll T., O'Connor C., O'Brien G., Molloy K., Ferrarotti I., Luisetti M., O'Neill S, Mc Elvaney G. Rare alpha-1 antitrypsin mutations in the Irish population. Eur Respir J. 2011, 38, Suppl 55, pp. 313.
16. Cichy J., Potempa J., Travis J, Biosynthesis of α1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem. 1997, 272, pp. 8250–5.
17. Chapman K. R., Stockley R. A., Dawkins C., Wilkes M. M., and Navickis R. J. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009, 6(3), pp. 177-84.
18. Crystal R. G. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990, 85, pp. 1343–1352.
19. Dawkins P. A., Dowson L. J., Guest P. J., Stockley R. A. Predictors of mortality in alpha-1-antitrypsin deficiency. Thorax. 2003, 58, pp. 1020-1026
20. De Meo D. L., Silverman E. K. Alpha 1-antitrypsin deficiency. 2: genetic aspects of alpha 1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax.2004, 59, pp. 259–264.
21. De Serres F. J. Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ Health Perspect. 2003, 111, pp. 1851-4.
22. De Serres F. J. Worldwide racial and ethnic distribution of alpha-1antitrypsin deficiency. Chest. 2002, 122, pp. 1818-29.
23. De Serres F. J., Blanco I., Fernández-Bustillo E. Estimated numbers and prevalence of PI*S and PI*Z deficiency alleles of α1-antitrypsin deficiency in Asia. Eur Respir J. 2006, 28, pp. 1091-1099
24. Dowson L. J., Guest P. J., Stockley R. A. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (Pi Z). Chest. 2002, 122, pp. 1247–55.
25. Edmonds B. K., Hodge J. A., Rietschel R. L. Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature. Pediatr Dermatol. 1991, 8, pp. 296–299.
26. Elliott P. R., Lomas D. A., Carrell R. W. et al. Inhibitory conformation of the reactive loop of α1-antitrypsin. Nat Struct Biol1996, 3, pp. 676–81.
27. Elliott P. R., Abrahams J. P., Lomas D. A. Wild type α1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol. 1998, 275, pp. 419–25.
28. Elliott P. R., Pei X. Y., Dafforn T. R et al. Topography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 2000, 9, pp. 1274–81.
29. Ferrarotti I., Scavini R., Campo I., Ottaviani S., Zorzetto M., Gorrini M., Luisetti M. Laboratory diagnosis of alpha1-antitrypsin deficiency. Translational reseach. 2007,150, pp. 267-74.
30. Ferrarotti I., Zorzetto M., Scabini R. P., Mazzola, Campo I, Luisetti M. A novel method for rapid genotypic identification of alpha 1-antitrypsin variants. Diagn Mol Pathol. 2004, 13 (3), pp. 160-3.
31. Fregonese L., Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet Journal of Rare Diseases. 2008, 3, pp. 16-18.
32. Greene C. M., Miller S. D., Carroll T., McLean C., O'Mahony M., Lawless M. W, O'Neill S. J., Taggart C. C., Mc Elvaney N. G. Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations. J Inherit Metab Dis. 2008, 31 pp. 21–34.
33. Harvard School of Public Health. Costly Non communicable Diseases on Rise in Developing World. http://www.hsph.harvard.edu/news/features/cover-age-in-the-media/global-health-noncommunicable-diseases-bloom/index.html. Date last accessed: July 8, 2011.
34. Hird M. F., Greenough A., Mieli-Vergani G. et al. Hyperinflation in children with liver disease due to alpha-1-antitrypsin deficiency. Pediatr Pulmonol. 2000, 11, pp. 212–216.
35. Hutchison D. C. Alpha1 antitrypsin deficiency in Europe; geographical distribution of Pi types S and Z. Respir Med.1998, 92, pp. 367-377.
36. Kim S. J., Woo J. R., Seo E. J. et al. A 2.1 Å resolution structure of an uncleaved α1-antitrypsin shows variability of the reactive centre and other loops. J Mol Biol. 2001, 306, pp. 109–19.
37. King M. A., Stone J. A., Diaz P. T., Mueller C. F., Becker W. J., Gadek J. E. Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology. 1996, 199, pp. 137–141.
38. Kozlova I. New in the diagnosis and treatment of COPD. Kazakhstan Medical Journal. 2012; 6:13-15
39. Lomas D. A., Mahadeva R. Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Klin Invest. 2002, 110, pp. 1585-90.
40. Luisetti M., Seersholm N. α1-Antitrypsin deficiency. Epidemiology of α1- antitrypsin deficiency. Thorax. 2004, 59, pp. 164-169
41. Mc Closkey S. C., Patel B. D., Hinchliffe S. J., et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med. 2001, 164, pp. 1419–24.
42. Memorandum from a WHO meeting α1-Antitrypsin deficiency. Bull World Health Organ 1997,75, pp. 397-415.
43. Miravitlles M., Herr C., Ferrarotti I., Jardi R., Rodriguez-Frias F., Luisetti M., Bals R. Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European centres. Eur Respir J.2010, 35, pp. 960-968.
44. Mornex J. F., Chytil-Weir A., Martinet Y. et al. Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals. J Clin Invest. 1986, 77, pp. 1952–61.
45. Perlmutter D. H., Daniels J. D., Auerbach H. S., et al. The α1-antitrypsin gene is expressed in a human intestinal epithelial cell line. J Biol Chem. 1989, 264, pp. 9485–90.
46. Piitulainen E., Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999;13(2):247-51.
47. Potempa J., Korzus E., Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994, 269, pp. 15957–60.
48. Rabe K. F., Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176, pp. 532–55.
49. Rao N. V., Wehner N. G., Marshall B. C. et al. Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structure and functional properties. J Biol Chem.1991, 266, pp. 9540–8.
50. Ryu S. E., Choi H. J., Kwon K. S. et al. The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved α1-antitrypsin at 2.7 Å. Structure. 1996, 4, pp. 1181–92.
51. Seersholm N., Wencker M., Banik N., Viskum K., Dirksen A., Kok-Jensen A., Konietzko N. Does alpha-1 antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1 antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaftzur Therapie von Lungenerkrankungen (WATL) Alpha-1 AT study group. EurRespir J. 1997, 10, pp. 260–3.
52. Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994, 49, pp. 695-8.
53. Seersholm N., Dirksen A., Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Eur Respir J. 1994, 7, pp. 1985-1987.
54. Seersholm N., Kok-Jensen A. Clinical features and prognosis of life-time non-smokers with severe alpa-1-antitrypsin deficiency. Thorax. 1998, 53, pp. 265-268.
55. Silverman E. K., Pierce J. A., Province M. A., Rao D. C., Campbell E. J. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989, 111, pp. 982-91.
56. Silverman E. K., Chapman H. A., Drazen J. M. et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157, pp. 1770–8.
57. Silverman E. K., Sandhaus R. A. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009, 360, pp. 2749–57.
58. Sobradillo V., Miravitlles M., Gabriel R., Jiménez-Ruiz C., Villasante C., Masa J. F., Viejo J. L., et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000, 118, pp. 981-9.
59. Stolk J, Seersholm N, Kalsheker N. Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int J Chron Obstruct Pulmon Dis. 2006, 1, pp. 151–60.
60. Stoller J. K., Aboussouan L. S. α1-antitrypsin deficiency. Lancet. 2005, 365, pp. 2225-36.
61. Stoller J. K., Smith P., Yang P., Spray J. Physical and social impact of alpha - 1-antitrypsin deficiency: results of a mail survey of the readership of a national newsletter. Cleve Clin J Med. 1994, 61, pp. 461-466.
62. Sveger T., Piitulainen E., Arborelius M. J. Lung function in adolescents with alpha 1-antitrypsin deficiency. Acta Paediatr. 1994, 83, pp. 1170–1173.
63. Tonelli A. R., Rouhani F., Li N., Schreck P., Brantly M. L. Alpha-1 antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009, 4, pp. 443–52.
64. Wall M., Moe E., Eisenberg J., et al., Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr. 1990, 116, pp. 248–251.
65. Wencker M., Banik N., Buhl R., Seidel R., Konietzko N. Long-term treatment of alpha-1 antitrypsin deficiency-related pulmonary emphysema with human alpha 1 - antitrypsin. Wissenschaftliche Arbeits gemein schaft zur Therapie von Lungener krankungen (WATL) – alpha -1 AT - study group. Eur Respir J. 1998, 11, pp. 428–33.
66. World Health Organization. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: a Comprehensive Approach. Geneva, WHO Press, 2007. P.317.
67. World Economic Forum. Global Risks 2010: a Global Risk Network Report. Geneva, World Economic Forum, 2010. p. 377.
68. Yang P., Bamlet W. R., Sun Z., Ebbert J. O., Aubry M. C., Krowka M. J., Taylor W. R., Marks R. S., Deschamps C., Swensen S. J. et al. Alpha 1 - antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest. 2005, 128, pp. 445–452.
Библиографическая ссылка
Жумагалиева А. Н. Санитарно-эпидемиологическая характеристика медицинских отходов лечебно-профилактических учреждений города Семей / / Наука и Здравоохранение. 2016. №1. С. 127-131.
Zhumagaliyeva A. N. Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease. Nauka i Zdravookhranenie [Science & Healthcare]. 2016, 1, pp. 127-131.
Жұмағалиева А. Н. Альфа-1 - Антитрипсин тапшылығы және өкпенің созылмалы обструктивті ауруы / / Ғылым және Денсаулық сақтау. 2016. №1. Б. 127-131.